Bone Biologics is a publicly traded company based in Boston, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development. Our lead product is a NELL-1 based bone graft substitute for spine fusion, targeting the rapidly growing orthobiologics market. Our goal is to offer patients superior safety with uncompromising efficacy relative to existing technologies. NELL-1 provides specific targeted regulation over bone regeneration in the presence of targeted osteogenic cells, as both demonstrated in the lab and through the use of animal testing, unlike any other current therapy. It has been shown not to form bone when applied to non-osteogenic cells such as myoblasts (a type of embryonic progenitor cell that differentiates to give rise to muscle cells) nor does it induce adipogenesis (the formation of fat that can occur within the bone matrix often exhibited as cysts) that results in weaker bone.
Our mission is to utilize the power of NELL-1 to improve clinical outcomes and reduce total health care delivery costs associated with spinal fusion. Bone Biologics is focused on bone repair and regeneration applications and is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.
The Bone Biologics leadership team consists of some of the top leaders and innovators of orthobiologics in regenerative medicine. Not only does our leadership provide strategic oversight of the Company, they contribute to the collective advancement of the industry. This leadership is instrumental in fulfilling our mission to improve clinical outcomes and reduce health care delivery costs associated with lumbar spinal fusion.
While Bone Biologics has chosen to focus its initial product development efforts in spinal fusion, we believe that this regenerative medicine technology has potential in the broader fields of bone regeneration and repair including osteoporosis, chondrocytes and applications using mesenchymal stem cells.
Bone Biologics was founded in 2004 by Dr. Chia Soo, MD/Vice-Chair and Professor, UCLA Hospital Dept of Orthopedic Surgery; Dr. Kang Ting DMD, DMSc/Professor, UCLA Dental School; and Dr. Benjamin Wu, DDS, PhD/Chair and Professor, UCLA Dept of Bioengineering.The Company was acquired in 2006 by MTF, the major shareholder and primary funder since the acquisition.
Headquartered in Boston, Massachusetts, USA, Bone Biologics became a public company in September 2014 and is focused on bone repair and regeneration applications. The company is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.
For information regarding our company and/or products, please complete the form below.